Prudential-Bache Securities’ R&D; Funding Corp. subsidiary has...
- Share via
Prudential-Bache Securities’ R&D; Funding Corp. subsidiary has pumped an additional $1.3 million into Synbiotics Corp., increasing its interest in the San Diego-based monoclonal antibody company to $9.8 million. Synbiotics, which is using the original investment to develop 11 veterinary products, will use the $1.3 million to develop an additional veterinary product.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
